Rankings
▼
Calendar
AMRX Q3 2018 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q3 2018 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$476M
+87.1% YoY
Gross Profit
$200M
42.0% margin
Operating Income
$75M
15.6% margin
Net Income
$7M
1.5% margin
EPS (Diluted)
$0.05
QoQ Revenue Growth
+15.2%
Cash Flow
Operating Cash Flow
$62M
Free Cash Flow
$25M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$4.6B
Total Liabilities
$3.7B
Stockholders' Equity
$501M
Cash & Equivalents
$165M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$476M
$255M
+87.1%
Gross Profit
$200M
$135M
+48.2%
Operating Income
$75M
$79M
-5.3%
Net Income
$7M
$27M
-74.0%
Revenue Segments
Yuvafem-Estradiol
$48M
30%
Rytary Family
$33M
21%
Epinephrine Auto-Injector Family (Generic Adrenaclick)
$30M
19%
Diclofenac Sodium Gel
$26M
16%
Aspirin;Dipyridamole ER Capsul
$23M
14%
← FY 2018
All Quarters
Q4 2018 →